Investigators' and institutions' financial conflicts of interest in clinica
l research raise serious questions about the objectivity of such research,
the safety of human subjects, and the threat to public trust in the integri
ty of clinical research. Yet the author makes clear that a conflict of inte
rest is a state of affairs, not a behavior, and therefore not automatically
a manifestation of improper actions. Indeed, conflicts of interest are qui
te common in complex settings such as those of academic medicine, and usual
ly pose no problem, both because of the safeguards already in place and the
integrity of most researchers. But it is clear that both non-financial con
flicts of interest (e.g., career advancement, peer recognition, garnering g
rants and publications) and financial ones are double-edged: they can motiv
ate individuals to do their best work but also can compromise judgment and
undermine objectivity. In particular, conflicts of interest involving money
, especially money from external sources, warrant special, targeted safegua
rds. And whether or not such conflicts of interest have actually created si
gnificant problems, academic medicine risks great peril if its leaders fail
to respond to the growing perception that such problems exist.
To foster public trust, the public needs to be better educated about how, w
ith proper safeguards, limited financial incentives in the conduct of clini
cal research can benefit everyone. In addition, safeguards against the down
sides of such financial incentives must be visibly strengthened. The author
offers eight suggestions for what academic medicine's leaders might do in
this regard (comply with existing full-disclosure requirements; establish p
rinciples governing institutional conflicts of interest; etc.). He closes b
y reiterating that the pursuit of clinical research depends entirely on the
ability and willingness of the research community to merit public trust.